Xocova

(Ensitrelvir)

Phase 2Small molecule

Shionogi

Xocova is one of 18 small molecule programs targeting COVID-19. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

FDA Application

NDA/BLA/ANDA regulatory filings

Pipeline

Status by Indication[3][1]

Indication

COVID-19Active, not recruiting

COVID-19Phase 2

Active, not recruiting

Competition

Competitive Landscape

1931 competitors in COVID-19

#DrugCompanyPhaseTrials

COVID-19 Vaccine

Moderna

Preclinical

27 2

Singulair

AstraZeneca

Preclinical

1 3

Xocova

Shionogi

Phase 2

1 4

Activella

Eli Lilly

Preclinical

—5

Proventil

Mylan Pharmaceuticals Inc

Preclinical

1 6

Nitrostat

VViatris Specialty LLC

Preclinical

1 7

SARS-COV-2 VACCINE

Moderna

Preclinical

2 8

Achromycin V

WWyeth-Lederle Vaccines

Statins

1 10

Disease-Modifying Anti-Rheumatic Drugs

Roche

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2027

Phase 2Recruiting

COVID-19

NCT05041907

Clinical

Trials by Indication[1]

Inflammation1 trial

Ensitrelvir for Viral Persistence and Inflammation in People Experiencing Long COVID

Active, not recruiting·TTimothy Henrich·Phase 2·NCT06161688·40 enrolled

COVID-191 trial

Finding Treatments for COVID-19: A Trial of Antiviral Pharmacodynamics in Early Symptomatic COVID-19 (PLATCOV)

Recruiting·UUniversity of Oxford·Phase 2·NCT05041907·3,800 enrolled

Interaction1 trial

A Drug-Drug Interaction Study of S-217622 With Combined Oral Contraceptives in Healthy Adult Female Participants

Completed· Shionogi logo

Shionogi·Phase 1·NCT06775730·24 enrolled

Regulatory

FDA Approval Timeline[4]

May 29, 2026

XOCOVA

NDA NDA220442

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for Ensitrelvir. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Ensitrelvir compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Ensitrelvir. EMBL-EBI & Wellcome Sanger Institute.
[4]
OpenFDA — FDA approval records (NDA NDA220442). U.S. Food & Drug Administration.
[5]
SEC EDGAR — Shionogi company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: Shionogi

Xocova

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2027

Trials by Indication[1]

Inflammation1 trial

COVID-191 trial

Interaction1 trial

FDA Approval Timeline[4]

References

Drug Info

Quick Facts

Related News